Next Article in Journal
Chitosan Hydrogel Beads Supported with Ceria for Boron Removal
Next Article in Special Issue
LOXL2—A New Target in Antifibrogenic Therapy?
Previous Article in Journal
Gene Expression in Developmental Stages of Schistosoma japonicum Provides Further Insight into the Importance of the Schistosome Insulin-Like Peptide
Previous Article in Special Issue
TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis
Article Menu
Issue 7 (April-1) cover image

Export Article

Open AccessArticle

Effects of Caffeine Treatment on Hepatopulmonary Syndrome in Biliary Cirrhotic Rats

1
Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan
2
Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 112, Taiwan
3
Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan
4
Chang Gung University College of Medicine and Division of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
5
Division of Gastroenterology, Department of Medicine, Cheng Hsin General Hospital, Taipei 112, Taiwan
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(7), 1566; https://doi.org/10.3390/ijms20071566
Received: 2 March 2019 / Revised: 22 March 2019 / Accepted: 25 March 2019 / Published: 28 March 2019
(This article belongs to the Special Issue Recent Advances in Pathophysiology of Fibrosis and Scarring)
  |  
PDF [10186 KB, uploaded 28 March 2019]
  |  

Abstract

Hepatopulmonary syndrome (HPS) is a lethal complication of cirrhosis characterized by hypoxia and overt intrapulmonary shunting. In this study, we investigated the effect of caffeine in rats with common bile duct ligation (CBDL)-induced liver cirrhosis and HPS. CBDL rats were randomly allocated to receive caffeine or vehicle for 14 days. On the 28th day after CBDL, mortality rate, hemodynamics, liver, and renal biochemistry parameters and arterial blood gas analysis were evaluated. Lung and liver were dissected for the evaluation of inflammation, angiogenesis and protein expressions. In another series with parallel groups, the intrapulmonary shunting was determined. Caffeine significantly reduced portal pressure (caffeine vs. control: 10.0 ± 3.7 vs. 17.0 ± 8.1 mmHg, p < 0.05) in CBDL rats. The mortality rate, mean arterial pressure, biochemistry data and hypoxia were similar between caffeine-treated and control groups. Caffeine alleviated liver fibrosis and intrahepatic angiogenesis but intrapulmonary inflammation and angiogenesis were not ameliorated. The hepatic VEGF/Rho-A protein expressions were down-regulated but the pulmonary inflammation- and angiogenesis-related protein expressions were not significantly altered by caffeine. Caffeine did not reduce the intrapulmonary shunting, either. Caffeine has been shown to significantly improve liver fibrosis, intrahepatic angiogenesis and portal hypertension in cirrhotic rats, however, it does not ameliorate HPS. View Full-Text
Keywords: caffeine; hepatopulmonary syndrome; liver cirrhosis caffeine; hepatopulmonary syndrome; liver cirrhosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Chang, C.-C.; Chuang, C.-L.; Tsai, M.-H.; Hsin, I.-F.; Hsu, S.-J.; Huang, H.-C.; Lee, F.-Y.; Lee, S.-D. Effects of Caffeine Treatment on Hepatopulmonary Syndrome in Biliary Cirrhotic Rats. Int. J. Mol. Sci. 2019, 20, 1566.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top